New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come

Journal of Central Nervous System Disease

Article

J. Nicholas¹  A. Boster¹  D. Pitt¹  B. Morgan-Followell¹  M.K. Racke¹ 

[1] The Ohio State University Medical Center, Department of Neurology, Division of Neuro-immunology, Columbus, Ohio.;

关键词: multiple sclerosis;    treatment;    natalizumab;    alemtuzumab;    daclizumab;    ocrelizumab;    ofatumumab;    fingolimod;    BG12;    laquinimod;    teriflunomide;   

DOI  :  10.4137/JCNSD.S6692

来源: Sage Journals

【 摘 要 】

The therapeutic landscape for multiple sclerosis (MS) is rapidly changing. Currently, there are eight FDA approved disease modifying therapies for MS including: IFN-β-1a (Avonex, Rebif), IFN-β-1b (Betaseron, Extavia), glatiramer acetate (Copaxone), mitoxantrone (Novantrone), natalizumab (Tysabri), and fingolimod (Gilenya). This review will highlight the experience to date and key clinical trials of the newest FDA approved agents, natalizumab and fingolimod. It will also review available efficacy and safety data on several promising therapies under active investigation including four monoclonal antibody therapies: alemtuzumab, daclizumab, ocrelizumab and ofatumumab and three oral agents: BG12, laquinimod, and teriflunomide. To conclude, we will discuss where each of these new therapies may best fit into treatment algorithms.

【 授权许可】

CC BY-NC   
© 2012 SAGE Publications.

【 图 表 】

Figure 5.

Figure 13.

Figure 4.

Figure 1.

Figure 3